ENTRY       D11054                      Drug
NAME        Ravulizumab (USAN/INN);
            Ravulizumab (genetical recombination) (JAN);
            Ultomiris (TN)
PRODUCT     ULTOMIRIS (Alexion Pharmaceuticals)
FORMULA     C6430H9888N1696O2028S48
EXACT_MASS  144846.9337
MOL_WEIGHT  144936.5781
SEQUENCE    (A chain)
            XVQLVQSGAE VKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE ILPGSGHTEY
            TENFKDRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYF FGSSPNWYFD VWGQGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
            GNVFSCSVLH EALHSHYTQK SLSLSLG
            (B chain)
            XVQLVQSGAE VKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE ILPGSGHTEY
            TENFKDRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYF FGSSPNWYFD VWGQGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
            GNVFSCSVLH EALHSHYTQK SLSLSLG
            (C chain)
            DIQMTQSPSS LSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYG ATNLADGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQN VLNTPLTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (D chain)
            DIQMTQSPSS LSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYG ATNLADGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQN VLNTPLTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A22-A96, A136-C214, A149^A205, A224-B224, A225-B225, A228-B228, A231-B231, A262-A322, A368-A426, B22-B96, B136-D214, B149-B205, B262-B322, B368-B426, C23-C88, C134-C194, D23-D88, D134-D194)
  TYPE      Peptide
REMARK      Therapeutic category: 6399
            ATC code: L04AA43
            Product: D11054<JP/US>
EFFICACY    Immunomodulator, Anti-complement C5 antibody
  DISEASE   Paroxysmal nocturnal hemoglobinuria [DS:H01053]
            Atypical hemolytic uremic syndrome [DS:H01434]
  TYPE      Monoclonal antibody
COMMENT     Treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)
TARGET      C5 [HSA:727] [KO:K03994]
  PATHWAY   hsa04610(727)  Complement and coagulation cascades
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA43 Ravulizumab
                  D11054  Ravulizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Complement Inhibitors
                Ravulizumab
                 D11054  Ravulizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D11054  Ravulizumab (USAN/INN); Ravulizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                C5
                 D11054  Ravulizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11054
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11054
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11054
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11054
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11054
DBLINKS     CAS: 1803171-55-2
            PubChem: 363669767
///
